Comparison · NCT04569084-deaths
Edaravone 105 mg (Once Daily) vs Edaravone 105mg (2 Weeks On/Off ): deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Edaravone 105 mg (Once Daily) vs Edaravone 105mg (2 Weeks On/Off ): deaths from any cause. Trial comparisons, record NCT04569084-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04569084-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0469 | 0.0249 | 0.0867 | wilson | |
| Risk in group 2 | 0.0833 | 0.0519 | 0.131 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0365 | -0.089 | 0.0142 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.563 | 0.255 | 1.24 | log | |
| Odds ratio, group 1 over group 2 | 0.541 | 0.233 | 1.26 | log | |
| Number needed to treat, for one fewer death from any cause on Edaravone 105 mg (Once Daily) than on Edaravone 105mg (2 Weeks On/Off ) | 27.4 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Edaravone 105 mg (Once Daily) | Oral edaravone 105 mg administered once daily (regimen denoted as Once Daily) in Cycles 1 through 12 | 9 | 192 | EG000 |
| Group 2 | Edaravone 105mg (2 Weeks On/Off ) | Oral edaravone 105 mg administered for 14 days, followed by placebo for 14 days in Cycle 1.~Subsequently, repeat oral edaravone 105 mg administered for 10 days followed by placebo for 18 days (regimen denoted as On/Off) in Cycles 2 through 12 | 16 | 192 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
- Up to 3 years
Source ClinicalTrials.gov
Trial
- Title
- Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS
- NCT number
- NCT04569084
- Phases
- PHASE3
- Conditions
- ALS
- Interventions
- MT-1186, Placebo
- Lead sponsor
- Shionogi
- Results first posted
- 2025-03-27
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04569084?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04569084-deaths